Akero Therapeutics, Inc.（纳斯达克股票代码：AKRO）首席运营官Jonathan Young于2025年8月12日通过多笔交易出售了12,500股普通股。这些交易的执行价格在47.21美元至48.61美元之间，总收益为597,325美元。此次交易发生之际，AKRO股价年初至今已上涨73%，尽管过去一周下跌了8.5%。根据 InvestingPro ...

市值38.4亿美元的Akero Therapeutics, Inc. (NASDAQ:AKRO)董事Jane Henderson于2025年8月12日以每股47.457美元的价格出售了3,000股普通股，总价值为142,371美元。尽管该股票在过去一周下跌了9%，但在过去一年中表现出色，回报率达94%。 同一天，Henderson还行权获得了3,000股Akero Therapeutics普通股， ...

2025年8月12日， Akero Therapeutics（AKRO）披露2笔公司内部人交易情况。董事Henderson Jane于2025年8月12日卖出3000股。 2025年8月12日 董事 Henderson Jane 2025年8月12日 卖出 3000 47.46 14.24万 2025年8月12日 董事 Henderson Jane 2025年8月12日 买入 3000 7.01 ...

Akero Therapeutics (AKRO) announced publication of 96-week final results from the Phase 2b HARMONY trial in The Lancet in adults with ...

Results support potential of efruxifermin (EFX) to reduce risk of fibrosis progression in patients with pre-cirrhotic (F2-F3) MASH ...

Week 96 data presented during a late-breaking oral session at EASL 2025 demonstrated the potential of EFX 50mg to reverse cirrhosis in high-need MASH subgroups, including patients with cryptogenic ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that all ...

--Akero Therapeutics, Inc., a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, will hold an investor ...

Akero Therapeutics' share price is tanking after biotech's NASH drug fails to meet its primary endpoint in a Phase 2B study. Find out why AKRO stock is a Buy.

Akero Therapeutics (NASDAQ: AKRO) announces the pricing of an underwritten public offering of 11 million shares of its common stock at a public offering price of $29.00 a share, for an expected ...

Morgan Stanley analyst Michael Ulz lowered the firm’s price target on Akero Therapeutics (AKRO) to $90 from $96 and keeps an Overweight rating on the shares. The company’s Q4 report was ...

Shares of Akero Therapeutics (AKRO 2.11%) were down more than 70% for the week as of Thursday's close, according to data provided by S&P Global Market Intelligence.